ストックスクリーナーアプリを入手
15.50
0.26%
0.04
Arcus Biosciences Inc (RCUS) 最新ニュース
Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week - Yahoo Finance
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Jane Street Group LLC - MarketBeat
State Street Corp Trims Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus Biosciences to Present at J.P. Morgan Healthcare Conference 2025Key Oncology Updates Expected - StockTitan
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 26,966 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
BNP Paribas Financial Markets Has $173,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
(RCUS) Trading Advice - Stock Traders Daily
Arcus Biosciences' SWOT analysis: stock outlook amid HIF2alpha and TIGIT progress - Investing.com
Estimating The Intrinsic Value Of Arcus Biosciences, Inc. (NYSE:RCUS) - Simply Wall St
Charles Schwab Investment Management Inc. Has $8.67 Million Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus Biosciences Announces New Employment Inducement Grants - Marketscreener.com
Arcus Biosciences Awards New Employee Equity Grants Under Inducement Plan - StockTitan
Fmr LLC Boosts Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Point72 Asset Management L.P. Increases Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
(RCUS) Investment Analysis and Advice - Stock Traders Daily
Arcus Biosciences' chief accounting officer sells $3,079 in stock - Investing.com
Arcus Biosciences' chief accounting officer sells $3,079 in stock By Investing.com - Investing.com Canada
Parkman Healthcare Partners LLC Acquires 610,219 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus Biosciences Grants New Employee Stock Options and RSUs in Latest Inducement Awards - StockTitan
Walleye Capital LLC Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - Benzinga
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Buy" by Analysts - MarketBeat
Suvretta Capital Management LLC Trims Position in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Algert Global LLC Has $1.73 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus up 4% following Merck Welireg kidney cancer data - MSN
When (RCUS) Moves Investors should Listen - Stock Traders Daily
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $14.24 Million Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
RCUS (Arcus Biosciences) Cash-to-Debt : 18.78 (As of Sep. 2024) - GuruFocus.com
Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking - Simply Wall St
Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2024 Earnings Call Transcript - MSN
Arcus Biosciences to Present at Evercore and Citi Healthcare Conferences in December | RCUS Stock News - StockTitan
Arcus Biosciences' SWOT analysis: biotech stock faces pivotal data releases - Investing.com
Arcus Biosciences' SWOT analysis: biotech stock faces pivotal data releases By Investing.com - Investing.com Australia
FMR LLC Bolsters Stake in Arcus Biosciences Inc - GuruFocus.com
Arcus Biosciences Awards Key Equity Grants to New Hires at $17.85 Per Share | RCUS Stock News - StockTitan
GSA Capital Partners LLP Raises Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
FY2024 Earnings Forecast for RCUS Issued By HC Wainwright - MarketBeat
Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report - Yahoo Finance
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Arcus Biosciences (NYSE:RCUS) Posts Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: S - GuruFocus.com
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of “Buy” from Analysts - Defense World
Analysts Set Arcus Biosciences, Inc. (NYSE:RCUS) Price Target at $33.67 - MarketBeat
Arcus Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arcus Biosciences Surges: 34% Cancer Trial Success, AstraZeneca Deal Boosts Q3 | RCUS Stock News - StockTitan
Arcus Biosciences (NYSE:RCUS) Receives "Neutral" Rating from HC Wainwright - MarketBeat
Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts - Benzinga
Arcus says Gilead-partnered cancer therapy cut death risk by 36% - Seeking Alpha
Arcus reports improved survival with cancer drug combo - Investing.com
Arcus Biosciences (RCUS) Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10 - StreetInsider.com
Arcus Bio's Cancer Drug Combo Cuts Death Risk by 36%, Doubles Survival Time in Lung Cancer Trial | RCUS Stock News - StockTitan
What To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 Earnings - GuruFocus.com
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):